Navigation Links
CIAs in Medical News

When CIAs Poisoned Capsule for Castro Stuck to the Freezer!

That the notorious US Central Intelligence Agency mounted innumerable attempts to kill its bete noire, Cubas Fidel Castro, is well known . Forget the politics of it all, the CIA has indeed been resourceful, even if they came to grief every time. Castro has already turned 80. Still the recen...

A Drug That Receives Regulatory Approval for Cognitive Impairment Associated With Schizophrenia Would Earn a Higher Patient Share in the United States Than in Europe

... CIAS. To date, no drugs are formally approved for cias and off-label treatment is sporadic. However, clin...and Merck could demonstrate advantages in treating cias when compared with donepezil (Eisai/Pfizer's Arice...en benefits in other indications in the hopes that cias patients will experience similar benefits," said D...

Memory Pharmaceuticals Closes Second Tranche of Equity Financing with The Stanley Medical Research Institute

...tional milestone related to the Phase 2a trial of MEM 3454 in CIAS. "We are extremely pleased with the progress of our Phase 2a trial of MEM 3454 in cias and that we have been able to translate our achievements into an opportunity to raise additional capital at favorable terms," stated Vaughn M. Kailian...

Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease

...ated with schizophrenia. The expanded agreement provides that Roche would have to make an additional milestone payment upon completion of the Phase 2a cias trial in order to maintain its license to MEM 3454. Under this agreement, Memory Pharmaceuticals and Roche actively collaborate on the discovery and ...
CIAs in Medical Technology

Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia

...87/MEM 3454 or placebo once daily for a period of eight weeks. The primary objective of the trial is to assess the effectiveness of R3487/MEM 3454 in cias using the MATRICS Consensus Cognitive Battery (MCCB). Secondary objectives include assessing the effectiveness of the drug to improve other symptoms o...

Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program

...ment associated with the completion of the Phase 2 cias trial as follows: $3.5 million in connection with ... million upon the completion of enrollment for the cias trial. The payment of the remaining $8.5 million w...the availability of top-line data from the Phase 2 cias trial, which is now expected in the second quarter...

Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia

.... To maintain its license to MEM 3454, Roche would have to make an additional milestone payment to the Company upon completion of the ongoing Phase 2a cias trial, which is expected to be completed in the fourth quarter of 2008. Evoked Potentials in Schizophrenia Electrophysiology measures have long be...

TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia

...plans to initiate a Phase II dose-ranging trial in cias during the first half of 2008. A secondary object...ned timing of the initiating of clinical trials in cias and xerostomia. Such statements are subject to num...ee that NGX267 will successfully treat symptoms of cias or xerostomia, the dose range may not be effective...
CIAs in Biological Technology

Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results

...he. During the quarter, we also achieved a milestone related to the Phase 2 cias trial under our equity financing agreement with SMRI, triggering an additio...me due 30 days following the availability of top-line data from the Phase 2 cias trial. In addition, Roche has agreed to fund all internal and external cost...

Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia

...rial is to assess the effectiveness of MEM 3454 in cias using the MATRICS Consensus Cognitive Battery (MCC... milestone payment upon completion of the Phase 2a cias trial to maintain its license to MEM 3454. The add...cted to cover the expenses related to the Phase 2a cias trial of MEM 3454. MEM 3454 is a partial agonist...
Other Tags
(Date:3/29/2015)... March 29, 2015 Final Cut ... transition from Pixel Film Studios, entitled TranSports. , ... exclusively for Final Cut Pro X,” said Christiana Austin, ... the tools needed to effortlessly transition using this cool ... a new and uniquely styled transition pack for Final ...
(Date:3/28/2015)... Tucson, AZ (PRWEB) March 28, 2015 Coffee ... could also help protect you from gum disease, researchers have ... protected against gum disease. , Coffee contains antioxidants. Antioxidants fight ... is the question researchers at Boston Univ. Henry M. Goldman ... published in the August 2014 issue of the Journal of ...
(Date:3/28/2015)... MILAN (PRWEB) March 28, 2015 ... thought-leaders in the fields of osteoporosis, osteoarthritis and ... on Osteoporosis, it may be the first time ... educational research forum that the hot-button topic is ... Based on the well-accepted scientific principles of Wolff’s ...
(Date:3/28/2015)... FL (PRWEB) March 28, 2015 ... conditions coverage is made available to all visitors who ... effective immediately. All members are encouraged to purchase the ... to avoid lack of proper coverage for pre-existing medical ... from one or two medical conditions with serious consequences ...
(Date:3/28/2015)... March 28, 2015 One in three ... to research presented today at the American Orthopaedic Society ... study examined the long term success of surgery for ... examined survey data from 242 patients who underwent ACL ... P. Roe, MBBS, FRACS, from North Sydney Orthopaedic and ...
Breaking Medicine News(10 mins):Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2
(Date:3/11/2015)... Mar. 11, 2015 Research and Markets ... "Access Control Market by Product, Application & By ... report to their offering. , This report ... reach $10.4 billion by 2020, with an estimated CAGR ... covers the products types such as contact cards & ...
(Date:3/10/2015)... , March 10, 2015   Tute Genomics , ... been selected by next-generation sequencing company PrimBio Research ... exome and targeted gene panel interpretation. PrimBio, ... adopted the most current technologies to support the work ... The company offers two types of exome sequencing services: ...
(Date:3/3/2015)... , March 3, 2015 ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... medicine, today announced the expansion of its ... Centers, ("Fred Hutch") Clinical Research Division ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
Other Contents